Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

EXPLAINED: Aptinyx | Rare Historical Photos

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary

Pfizer (NYSE:PFE) announced positive top-line data from the Phase 3 clinical trial RENOIR investigating its bivalent RSV prefusion F vaccine candidate, RSVpreF, when administered to adults 60 years of age or older. Pfizer, Inc. shares traded in a range of $47.27 to $47.95 on day volume of 14.45 million shares, closed…

Benzinga's Top Ratings Upgrades, Downgrades For August 16, 2022

Benzinga's Top Ratings Upgrades, Downgrades For August 16, 2022

Recap Of Friday's Biotech Catalysts - End Of the Day Summary

Recap Of Friday's Biotech Catalysts - End Of the Day Summary

Pfizer (NYSE:PFE) announced positive top-line results from its pivotal U.S. Phase 3 study in infants evaluating its 20-valent pneumococcal conjugate vaccine candidate (20vPnC) for the prevention of invasive pneumococcal disease (IPD). The study met two co-primary objectives, associated with immunogenicity responses. Pfizer shares traded in a range of $48.55 to…

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Expert Ratings for Aptinyx

Within the last quarter, Aptinyx (NASDAQ:APTX) has observed the following analyst ratings:

Recap: Aptinyx Q1 Earnings

Aptinyx (NASDAQ:APTX) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Aptinyx beat estimated earnings by 3.33%, reporting an EPS of $-0.29 versus an estimate of $-0.3.

Expert Ratings for Aptinyx

Within the last quarter, Aptinyx (NASDAQ:APTX) has observed the following analyst ratings:

The Daily Biotech Pulse: Pfizer Goes Shopping, AstraZeneca Inks Bispecific Antibody Deal, Aptinyx Faces Clinical Study Setback, Erytech Jumps On Data And More

Here's a roundup of top developments in the biotech space over the last 24 hours:

inkl

Read news from The Economist, FT, and more,
with one subscription

Aptinyx: Q4 Earnings Insights

Aptinyx: Q4 Earnings Insights

Aptinyx (NASDAQ:APTX) reported its Q4 earnings results on Wednesday, March 23, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Aptinyx beat estimated earnings by 17.14%, reporting an EPS of $-0.29 versus an estimate of $-0.35.

Earnings Preview For Aptinyx

Earnings Preview For Aptinyx

Aptinyx (NASDAQ:APTX) is set to give its latest quarterly earnings report on Wednesday, 2022-03-23. Here's what investors need to know before the announcement. Analysts estimate that Aptinyx will report an earnings per share (EPS) of $-0.35.

1

Organisations

European Commission

Bed, Bath & Beyond

US Food and Drug Administration

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

390,703 stories

142,672 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play